Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval - Top-Institutions - MDSpire

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval

  • By

  • Ayalew Tefferi

  • Animesh Pardanani

  • March 18, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Stem Cell Transplantation

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Research

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Bone Marrow Transplantation

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Clinical Trials

  • #5

    University of Pennsylvania Abramson Cancer Center
    University of Pennsylvania Abramson Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Translational Research

Original Source(s)

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval

  • by Ayalew Tefferi, Animesh Pardanani

  • March 18, 2024

Related Content

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Crossing the line: blood transfusion thresholds in ECMO

Assessment of Clinical Complications and Treatment Approaches in Non-Transfusion-Dependent α- and β-Thalassemia Patients Compared to Matched Controls: A Retrospective Analysis Utilizing Administrative Claims Data in the United States